search
Back to results

Treatment of Patients With Fecal Incontinence

Primary Purpose

Fecal Incontinence

Status
Terminated
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Biofeedback Therapy for Fecal Incontinence: A Randomized Control Study
control group
Sponsored by
US Department of Veterans Affairs
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Fecal Incontinence focused on measuring adequate relief, anorectal manometry, biofeedback therapy, fecal incontinence

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Male or female patient with inadequate relief of fecal incontinence symptoms after documented management in the primary care setting. They must have: a mini-mental status score of > 18 an "up and go" test score of < 30 seconds bowel habit diary showing > one episode of fecal incontinence episode per week Exclusion Criteria: patients who previously underwent a course of biofeedback for fecal incontinence age < 18 years major neurological disease significant cognitive impairment (mini mental status examination score < 18), functional impairment (up and go score of > 30 seconds) active inflammatory bowel disease history of spinal cord injury rectal resection ileal pouch procedures latex allergy significantly distressed and unable to consider informed consent issues adequately needing urgent medical referral insufficient written English skills to complete the questionnaires require surgery

Sites / Locations

  • VA Greater Los Angeles Healthcare System, Sepulveda, CA

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Arm 1

Arm 2

Arm Description

Control group of patients with fecal incontinence which would be given medical therapy and exercises to perform as treatment.

Study group of patients with fecal incontinence which would be given biofeedback therapy and exercises to perform as treatment.

Outcomes

Primary Outcome Measures

Patient Report of "Adequate Relief" From FI Symptoms With a "Yes" Answer Will be Used as Primary Outcome Variable. Data Will be Recorded at End of Treatment. A "Responder" Will be Defined as One Who Provides a "Yes" Answer.
Only reporting the results of participants who reported adequate relief.

Secondary Outcome Measures

Change in Anorectal Physiologic Tests (Absolute Squeeze Pressure)
Measurement of pressure changes by a colonoscope as recorded by a manometric catheter connected to a Polygraph transducer.

Full Information

First Posted
February 13, 2006
Last Updated
August 13, 2015
Sponsor
US Department of Veterans Affairs
search

1. Study Identification

Unique Protocol Identification Number
NCT00292318
Brief Title
Treatment of Patients With Fecal Incontinence
Official Title
Biofeedback Therapy for Fecal Incontinence a Randomized Control Trial
Study Type
Interventional

2. Study Status

Record Verification Date
August 2015
Overall Recruitment Status
Terminated
Why Stopped
Unable to continue due to medical equipment necessary for research study was removed from facility.
Study Start Date
January 2008 (undefined)
Primary Completion Date
September 2012 (Actual)
Study Completion Date
September 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
US Department of Veterans Affairs

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to determine if a behavioral treatment method called biofeedback will reduce the frequency of episodes of leakage of fecal material in patient suffering from fecal incontinence.
Detailed Description
Fecal incontinence (FI) is a devastating condition that causes psychological stress, shame, embarrassment, and social isolation. It has a major impact on quality of life of patients and their families. It complicates medical illnesses and management, has major economic consequences and can contribute to early nursing home placement. Although FI affects 2.2% to 11% of the general population, the magnitude of the problem is underestimated, since most patients do not discuss this silent affliction with their care providers. In uncontrolled studies of biofeedback for FI, including our preliminary observations in male veterans without anal sphincter injury, improvement was observed in up to 80% of patients. However, it may not be appropriate for all patients. One recent randomized, controlled trial in predominantly (93% women) female patients, many (> 60%) with post-obstetrical anal sphincter injury, reports that biofeedback is no more effective than medical therapy alone. The trial provides data for the formulation of an evidence-based approach to treat FI in female veterans. There are no randomized, controlled data on the effectiveness of biofeedback for FI in male patients. A randomized, controlled trial is needed to assess the effectiveness of multi-component biofeedback therapy versus standard medical therapy in man. The immediate objectives of the current proposal are to evaluate the effectiveness of biofeedback treatment for FI and to identify baseline patient characteristics that will predict improvement and adequate relief in FI symptoms following treatment. This will lead directly to our long-term goal of providing optimal treatment for FI by tailoring biofeedback plus medical therapy to each patient's needs, based on sound clinical evidence. This project is a prospective, randomized, controlled clinical trial comparing two treatments for FI among patients who have failed medical treatment under the care of their primary care providers and are referred for evaluation and management of current FI. As part of standard care, all referred patients will receive a history and physical examination, including medical, surgical, FI-specific symptoms and physical findings (general, mobility, mental status and anorectal examination). Those who meet inclusion criteria and who agree to participate will be randomly assigned to one of 2 study arms: 1. medical therapy alone, 2. medical therapy + sphincter strength + sensation + coordination training. Baseline data will also include adequate relief measure, incontinence scores based on bowel habit diary, anorectal parameters based on manometric and sensory testing, general and FI-specific quality of life, depression, anxiety, and expectation of improvement following treatment. All questionnaires will be based on published, validated instruments. Patients will be treated in six biweekly sessions (3 months). Medical therapy (six 40 - 60 minute sessions) includes advice, medication for constipation/diarrhea, and instruction related to empiric anal sphincter exercises (group 1). Biofeedback treatment (six 40 - 60 minute sessions) includes medical therapy plus all components of biofeedback (groups 2). Follow up data will be obtained in all patients at the end of treatment (3 months) and by mailed questionnaires at 12 months after completion of treatment or dropout. We can determine if biofeedback plus medical therapy will be superior to medical therapy alone in providing FI symptom relief. The possibility that more patients will report relief of FI symptoms when specific deficit(s) detected at baseline testing show(s) improvement with treatment. The influence of co-variables on results of treatment can also be determined. Our long term goal is to develop a clinically relevant strategy that will be cost-effect for the management of FI in VA patients (predominantly male) within the organizational frame work of primary and subspecialty care. If biofeedback treatment is proven to be effective, and VA patients can be offered therapy components with optimal likelihood of success, the obvious benefit to our VA patients is abatement of the silent affliction of FI and improvement in patient satisfaction and quality of life. Further study will focus on a multi-site cooperative study to assess which component of biofeedback is most instrumental in bringing about improvement and relief in patients with specific deficits.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Fecal Incontinence
Keywords
adequate relief, anorectal manometry, biofeedback therapy, fecal incontinence

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
7 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Arm 1
Arm Type
Active Comparator
Arm Description
Control group of patients with fecal incontinence which would be given medical therapy and exercises to perform as treatment.
Arm Title
Arm 2
Arm Type
Experimental
Arm Description
Study group of patients with fecal incontinence which would be given biofeedback therapy and exercises to perform as treatment.
Intervention Type
Behavioral
Intervention Name(s)
Biofeedback Therapy for Fecal Incontinence: A Randomized Control Study
Intervention Description
Patients who have more than one episode per week of fecal incontinence would be enrolled and randomized into either the control group (medical counseling and exercises) or study group (biofeedback therapy, medical counseling, and sphincter exercises) for seven sessions to assist with their medical problem.
Intervention Type
Behavioral
Intervention Name(s)
control group
Intervention Description
Medical counseling and ano-sphinctal exercises.
Primary Outcome Measure Information:
Title
Patient Report of "Adequate Relief" From FI Symptoms With a "Yes" Answer Will be Used as Primary Outcome Variable. Data Will be Recorded at End of Treatment. A "Responder" Will be Defined as One Who Provides a "Yes" Answer.
Description
Only reporting the results of participants who reported adequate relief.
Time Frame
The primary outcome will be determined at the end of the study which will be 20 weeks after starting the study.
Secondary Outcome Measure Information:
Title
Change in Anorectal Physiologic Tests (Absolute Squeeze Pressure)
Description
Measurement of pressure changes by a colonoscope as recorded by a manometric catheter connected to a Polygraph transducer.
Time Frame
The secondary outcome will be determined at the end of the study which will be 20 weeks after starting the study.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female patient with inadequate relief of fecal incontinence symptoms after documented management in the primary care setting. They must have: a mini-mental status score of > 18 an "up and go" test score of < 30 seconds bowel habit diary showing > one episode of fecal incontinence episode per week Exclusion Criteria: patients who previously underwent a course of biofeedback for fecal incontinence age < 18 years major neurological disease significant cognitive impairment (mini mental status examination score < 18), functional impairment (up and go score of > 30 seconds) active inflammatory bowel disease history of spinal cord injury rectal resection ileal pouch procedures latex allergy significantly distressed and unable to consider informed consent issues adequately needing urgent medical referral insufficient written English skills to complete the questionnaires require surgery
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Felix W Leung, MD
Organizational Affiliation
VA Greater Los Angeles Healthcare System, Sepulveda, CA
Official's Role
Principal Investigator
Facility Information:
Facility Name
VA Greater Los Angeles Healthcare System, Sepulveda, CA
City
Sepulveda
State/Province
California
ZIP/Postal Code
91343
Country
United States

12. IPD Sharing Statement

Links:
URL
http://www.aboutincontinence.org/
Description
One of the family of web sites by the international Organization for Functional Gastrointestinal Disorders (IFFGD)

Learn more about this trial

Treatment of Patients With Fecal Incontinence

We'll reach out to this number within 24 hrs